These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21190793)

  • 1. Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow.
    Retz M; Rotering J; Nawroth R; Buchner A; Stöckle M; Gschwend JE; Lehmann J
    Eur Urol; 2011 Aug; 60(2):231-8. PubMed ID: 21190793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular staging of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: comparison with standard histological staging.
    Ribal MJ; Mengual L; Marín M; Algaba F; Ars E; Fernández PL; Oliva R; Villavicencio H; Alcaraz A
    Anticancer Res; 2006; 26(1A):411-9. PubMed ID: 16475726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
    Hautmann RE; de Petriconi RC; Pfeiffer C; Volkmer BG
    Eur Urol; 2012 May; 61(5):1039-47. PubMed ID: 22381169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.
    Koga T; Tokunaga E; Sumiyoshi Y; Oki E; Oda S; Takahashi I; Kakeji Y; Baba H; Maehara Y
    Hepatogastroenterology; 2008; 55(84):1131-5. PubMed ID: 18705345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy.
    May M; Herrmann E; Bolenz C; Tiemann A; Brookman-May S; Fritsche HM; Burger M; Buchner A; Gratzke C; Wülfing C; Trojan L; Ellinger J; Tilki D; Gilfrich C; Höfner T; Roigas J; Zacharias M; Gunia S; Wieland WF; Hohenfellner M; Michel MS; Haferkamp A; Müller SC; Stief CG; Bastian PJ
    Eur Urol; 2011 May; 59(5):712-8. PubMed ID: 21296488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
    Rink M; Chun FK; Dahlem R; Soave A; Minner S; Hansen J; Stoupiec M; Coith C; Kluth LA; Ahyai SA; Friedrich MG; Shariat SF; Fisch M; Pantel K; Riethdorf S
    Eur Urol; 2012 Apr; 61(4):810-7. PubMed ID: 22277196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disseminated tumor cells in bone marrow of patients with transitional cell carcinoma: immunocytochemical detection and correlation with established prognostic indicators.
    Hofmann T; Riesenberg R; Buchner A; Zimmermann W; Hofstetter A; Oberneder R
    J Urol; 2003 Apr; 169(4):1303-7. PubMed ID: 12629348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.
    van Onna IE; Oddens JR; Kok ET; van Moorselaar RJ; Bosch JL; Battermann JJ
    Eur Urol; 2009 Jul; 56(1):113-21. PubMed ID: 18722048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?
    Gazquez C; Ribal MJ; Marín-Aguilera M; Kayed H; Fernández PL; Mengual L; Alcaraz A
    BJU Int; 2012 Nov; 110(9):1310-6. PubMed ID: 22416928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma.
    Rioja J; Bandrés E; Rosell Costa D; Rincón A; López I; Zudaire Bergera JJ; García Foncillas J; Gil MJ; Panizo A; Plaza L; Rioja LA; Berián Polo JM
    BJU Int; 2011 Jun; 107(11):1833-8. PubMed ID: 20840328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis.
    Illert B; Fein M; Otto C; Cording F; Stehle D; Thiede A; Timmermann W
    Scand J Gastroenterol; 2005 Jul; 40(7):843-9. PubMed ID: 16109661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma.
    Copp HL; Chin JL; Conaway M; Theodorescu D
    Cancer; 2006 Jul; 107(1):60-6. PubMed ID: 16691580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
    Thomas F; Noon AP; Rubin N; Goepel JR; Catto JW
    Eur Urol; 2013 Jan; 63(1):145-54. PubMed ID: 22985746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    J Urol; 2004 Apr; 171(4):1461-6. PubMed ID: 15017198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.